The intervention of Jianpifuwei granule on mucosal injury of precancerous lesion of gastric cancer via the IL-6/JAK/STAT3 axis and its mechanisms
DOI：10.3872/j.issn.1007-385x.2025.04.007
- VernacularTitle:健脾复胃颗粒通过IL-6/JAK/STAT3轴干预胃癌前病变黏膜损伤及其机制
- Author:
KANG Juying1,2,3
1
,
2
,
3
,
4
,
5
;
GUAN Huiying4
1
,
2
,
3
,
4
,
5
;
LI Peirun3
1
,
2
,
3
,
4
,
5
;
ZHANG Liming4
1
,
2
,
3
,
4
,
5
;
DUAN Yongqiang5
1
,
2
,
3
,
4
,
5
Author Information
1. The Graduate School, China Academy of Chinese Medical Sciences, Beijing 100700, China;
2. Ningxia Hui Medical Research Institute, Yinchuan 750021, Ningxia, China;
3. Department of Spleen and Stomach Diseases, Ningxia Traditional Chinese Medicine Hospital, Yinchuan 750021, Ningxia, China;
4. College of Pharmacy, Ningxia Medical University, Yinchuan 750004, Ningxia, China;
5. College of Traditional Chinese Medicine, Ningxia Medical University, Yinchuan 750004, Ningxia, China
- Publication Type:Journal Article
- Keywords:
健脾复胃颗粒；胃癌癌前病变；IL-6/JAK/STAT3信号通路
- From:
Chinese Journal of Cancer Biotherapy
2025;32(4):392-397
- CountryChina
- Language:Chinese
-
Abstract:
[摘 要] 目的：探讨健脾复胃颗粒（JPFWG）通过调控IL-6/JAK/STAT3信号通路对胃癌前病变（PLGC）大鼠胃黏膜损伤的干预效果及其作用机制。方法：采用MNNG联合复合因素造模法建立PLGC模型大鼠，随机分为6组（20只/组）：空白组（未处理）、模型组（给予生理盐水）、维酶素组（0.05 g/mL维酶素）、JPFWG低剂量组（JPFWG-L，0.088 g/mL）、JPFWG中剂量组（JPFWG-M，0.176 g/mL）、JPFWG高剂量组（JPFWG-H，0.351 g/mL）。各治疗组大鼠分别给予相应药物处理12周后，麻醉处死动物并取胃组织标本。采用H-E染色法观察胃黏膜的病理变化，通过免疫组化、qPCR和WB法检测胃黏膜组织中IL-6介导的JAK/STAT3信号通路相关因子（包括IL-6、JAK、STAT3）及其下游靶基因c-Myc、cyclin D1的 mRNA和蛋白的表达水平。结果：与模型组相比，维酶素组和JPFWG-L、JPFWG-M、JPFWG-H组大鼠胃黏膜炎性细胞浸润均减少，病理状态改善以JPFWG-H组最明显；IL-6、JAK1、STAT3蛋白表达显著降低（P < 0.05或P < 0.01）；维酶素组和JPFWG-H组大鼠胃黏膜组织中c-Myc、cyclin D1的 mRNA和蛋白表达均显著降低（P < 0.05或P < 0.01）。结论：JPFWG能够改善PLGC大鼠胃黏膜的组织病理变化，其机制可能是通过调控IL-6/JAK/STAT3信号通路，进而下调c-Myc、cyclin D1的表达，从而阻断炎-癌转化过程。
- Full text:202505211022289465620250407.pdf
